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Summary
Hemostasis and fibrinolysis, the biological processes that maintain proper blood flow, are the
consequence of a complex series of cascading enzymatic reactions. Serine proteases involved in these
processes are regulated by feedback loops, local cofactor molecules, and serine protease inhibitors
(serpins). The delicate balance between proteolytic and inhibitory reactions in hemostasis and
fibrinolysis, described by the coagulation, protein C and fibrinolytic pathways, can be disrupted,
resulting in the pathological conditions of thrombosis or abnormal bleeding. Medicine capitalizes on
the importance of serpins, using therapeutics to manipulate the serpin-protease reactions for the
treatment and prevention of thrombosis and hemorrhage. Therefore, investigation of serpins, their
cofactors, and their structure-function relationships is imperative for the development of state-of-
the-art pharmaceuticals for the selective fine-tuning of hemostasis and fibrinolysis. This review
describes key serpins important in the regulation of these pathways: antithrombin, heparin cofactor
II, protein Z-dependent protease inhibitor, α1-protease inhibitor, protein C inhibitor, α2-antiplasmin
and plasminogen activator inhibitor-1. We focus on the biological function, the important structural
elements, their known non-hemostatic roles, the pathologies related to deficiencies or dysfunction,
and the therapeutic roles of specific serpins.
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Introduction
Blood flow is maintained by the proper balance of hemostasis and fibrinolysis, an
interdependent network of physiological processes and succession of proteolytic reactions.
Hemostasis, the physiological cessation of bleeding, involves the interaction of
vasoconstriction, platelet aggregation and coagulation. The end result of coagulation is the
deposition of cross-linked fibrin polymers to form blood clots. Both the protein C and the
fibrinolytic pathways are activated by the coagulation pathway and serve to restrict excessive
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clot formation or thrombosis. The enzymatic reactions that propel these pathways are
dominated by serine proteases and are subject to control by serpins and their local cofactors.
Dysfunction, deficiencies or over-expression of serpins can cause either abnormal bleeding or
thrombosis. Investigations into the structure and related activities of serpins, their target
proteases and cofactors have provided valuable information regarding both serpin-related
disease states and potential mechanisms by which medicine can manipulate serpin-protease
interactions for the treatment and prevention of thrombosis and bleeding.
Hemostasis
Coagulation pathway
The factors of the coagulation pathway generally circulate in an inactive state until they are
activated through proteolysis by an upstream factor. While the end goal of coagulation is fibrin
polymerization, the most crucial feature of the coagulation pathway is the generation of
thrombin (Fig. 1). Thrombin is responsible for cleaving fibrinogen to fibrin, activating factor
(F) XIII to FXIIIa (which cross-links fibrin), activating platelets, and positively feeding back
into the cycle by activating upstream factors [1].
Thrombin generation is initiated when damage to a vessel wall exposes the blood to tissue
factor (TF) in the subendothelium [2]. TF is also expressed by activated platelets and leukocytes
[3]. Therefore, coagulation can also be initiated by inflammation. TF forms a complex with
FVIIa and activates FX. Together, FVa and FXa form the prothrombinase complex, which then
cleaves a small amount of prothrombin (FII) to thrombin (FIIa). This small amount of thrombin
activates platelets, FV, FVIII and FXI, feeding back into the cycle to increase thrombin
formation. Factor IXa, previously activated by either TF-VIIa or by FXIa on the platelet
surface, and FVIIIa in the presence of calcium, complex on the platelet surface to form the
platelet tenase complex. Platelet tenase activates more FX, which with FVa, generates a
‘thrombin burst’ (Fig. 1). It is this burst of thrombin rather than the initial thrombin activation
that is crucial for the formation of a stable hemostatic plug [2].
In addition to its role in hemostasis, thrombin regulates many proinflammatory processes
including leukocyte adhesion molecule expression on the endothelium, platelet activation,
leukocyte chemotaxis and endothelial cell production of prothrombotic factors [4]. Thrombin
is also a potent growth factor, initiating endothelial, fibroblast and smooth muscle cell
proliferation and up-regulating other cytokines and growth factors [5]. These activities have
been attributed to proteolytic cleavage of insulin-like growth factor binding proteins [6] and
protease activated receptors -1, -3 and -4 (PAR-1, -3, -4) [7] on cell surfaces, and account for
thrombin’s central role in atherosclerotic lesion formation [8].
Coagulation is regulated predominantly by antithrombin (AT) [9], tissue factor pathway
inhibitor (TFPI) [10], the protein C pathway [11] and to a lesser extent heparin cofactor II
(HCII) [12] and protein Z-dependent protease inhibitor (ZPI) [13]. Protein C inhibitor (PCI)
and plasminogen activator inhibitor-1 (PAI-1) may also contribute by inhibiting thrombin
[14,15]. TFPI is not a member of the serpin family and so will not be discussed in this paper.
Protein C pathway
The protein C pathway works in hemostasis to control thrombin formation in the area
surrounding the clot [16]. The zymogen protein C (PC) is localized to the endothelium by
endothelial cell protein C receptor (EPCR) [17]. Thrombin, generated via the coagulation
pathway, is localized to the endothelium by binding to the integral membrane protein,
thrombomodulin (TM). TM occupies exosite I on thrombin, which is needed for fibrinogen
binding and cleavage, thus reducing thrombin’s procoagulant activities [18]. However, on the
endothelial cell surface TM bound thrombin is able to cleave PC to activated protein C (APC),
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a serine protease [19]. In the presence of protein S, APC inactivates FVa and FVIIIa [20] (Fig.
1). This limits further thrombin generation on the clot periphery where the endothelium is not
damaged [21].
The protein C pathway is also associated with non-hemostatic functions. APC has been shown
to be an anti-inflammatory protein [22,23] and modulates gene expression [24]. It also enhances
vascular permeability by signaling through both PAR-1 and sphingosine 1-phosphate
receptor-1 [25]. In focal ischemic stroke animal models, APC treatment restored blood flow,
and reduced infarct volume and inflammation [26]. These neuroprotective effects of APC were
shown to be mediated through EPCR, PAR-1 [27] and PAR-3 [28]. In the PROWESS Study,
patients diagnosed with severe sepsis were treated with recombinant human APC, resulting in
a mortality reduction of 19.4% [29].
The proteolytic activity of APC is regulated predominantly by protein C inhibitor (PCI) [9].
Additionally, plasminogen activator inhibitor-1 (PAI-1) [30] and α1-protease inhibitor (α1PI)
[31] have been shown to inhibit APC, although their role in hemostasis is not well understood.
Fibrinolysis
Fibrinolytic pathway
Fibrinolysis is the physiological breakdown of fibrin to limit and resolve blood clots [32].
Fibrin is degraded primarily by the serine protease, plasmin, which circulates as a zymogen,
plasminogen. In an auto-regulatory manner, fibrin serves as both the cofactor for the activation
of plasminogen and the substrate for plasmin (Fig. 1). In the presence of fibrin, tissue
plasminogen activator (tPA) cleaves plasminogen to plasmin, which proteolyzes the fibrin.
Because it is a necessary cofactor for the reaction, the degradation of fibrin limits further
activation of plasminogen [33-35]. The serine protease, tPA, is synthesized and released by
endothelial cells [32]. In addition to binding fibrin, tPA binds Annexin II (AnII) and other
receptors on endothelial cell and platelet surfaces [36]. Thus, plasmin generation and
fibrinolysis are restricted to the site of thrombus formation.
In addition to its role in fibrinolysis, plasmin has other physiological functions as evidenced
by its ability to degrade components of the extracellular matrix [37] and activate matrix
metalloproteases 2 and 9 [38,39]. Plasminogen can also be converted to plasmin by the serine
protease, urokinase plasminogen activator (uPA) [37]. Urokinase-catalyzed events are
localized on the cell surface through the uPA receptor (uPAR). Complex formation and
subsequent reactions are thought to be more important during pericellular proteolysis, cell
adhesion and migration than they are for vascular fibrinolysis [32]. These additional functions
contribute to the role of the fibrinolytic pathway in cancer [37,40,41].
Fibrinolysis is controlled predominantly by α2-antiplasmin (α2AP) [42], PAI-1 [33,43] and
thrombin activatable fibrinolysis inhibitor (TAFI) [44]. PCI can inhibit tPA and uPA [45,46],
but its role in fibrinolysis is unclear. TAFI is not a member of the serpin family and so will not
be discussed in this paper.
Serpin overview
Serpins
Serpins are a superfamily of proteins classified into 16 clades (A-P). The systematic name of
each serpin is, SERPINXy where X is the clade and y is the number within the clade [47].
Serpins have been identified in the genomes of organisms representing all of the branches of
life (Bacteria, Archaea, Eukarya and Viruses), and the genome of humans contains c. 36 serpins
[48]. While serpins are named for their ability to inhibit serine proteases (of the chymotrypsin
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family) (Table 1), some are capable of cross-class inhibition of proteases from the subtilisin,
papain and caspase families. In addition, some serpins utterly lack protease inhibitory activity
and serve other roles, such as hormone transporters, molecular chaperones or catalysts for DNA
condensation. Serpins are typically composed of c. 400 amino acids, but can have large N-,
C-terminal or internal insertion loops [47]. Serpins can also be post-translationally modified
by glycosylation, sulfation, phosphorylation and oxidation to alter their function. In spite of a
low overall primary sequence identity for the family, serpins share a highly conserved three-
dimensional fold comprised of a bundle of 9 α-helices (A-I) and a β-sandwich composed of
three β-sheets (A-C) (Fig. 2A). It is useful to view a serpin in the ‘classic orientation’ to
illustrate the important structural features (Fig. 2A, left panel). In this view the main β-sheet
A is facing and the reactive site loop (RSL) is on top. The RSL is typically composed of 20
amino acids running from P17 at the N-terminus (at the C-terminal end of strand 5A) to P3′ at
the C-terminal end (using the nomenclature of Schechter and Berger, where residues are
numbered from the scissile P1-P1′ bond). In the normal native state of a serpin, β-sheet A is
composed of five strands and the RSL (bridging the C-terminus of strand 5A to the N-terminus
of strand 1C) is exposed. This state is, however, not the most stable. An astounding increase
in thermodynamic stability (best estimate - 32 kcal mol-1) [49] can be achieved through the
incorporation of the RSL into β-sheet A, triggered either through extension of strand 1C (to
form the so-called ‘latent’ state), or through proteolytic nicking anywhere near the scissile bond
(the cleaved state). The metastability of the native serpin is critical for its unusual mechanism
of protease inhibition [50].
The serpin mechanism of protease inhibition
The serpin mechanism of protease inhibition has been worked out over the last 20 years through
a series of biochemical, fluorescence and structural studies. A minimalist kinetic scheme is
composed of two steps: the formation of the encounter complex (also known as the Michaelis
complex) where the sequence of the RSL is recognized by the protease as a substrate; and the
formation of a final covalent complex where the protease is trapped in an inactive state (Fig.
2B). The rates of formation and dissociation of the reversible Michaelis complex, along with
colocalization in tissues, determines the specificity of the serpin-protease interaction [51,52].
While the obligate RSL-active site contacts contribute significantly to the formation of the
Michaelis complexes, exosite interactions may also be involved. As with actual substrates of
serine proteases, this step is followed by the nucleophilic attack of the peptide bond between
the P1-P1′ residues by the catalytic Ser195 of the protease. This ultimately results in the
formation of a covalent ester bond between the P1 residue and Ser195 of the protease (acyl-
enzyme intermediate), and then separation of the P’ residues from the active site of the protease.
At this stage the serpin rapidly adopts its lowest energy conformation through the incorporation
of the N-terminal portion of the RSL into β-sheet A. The tethered protease is thus flung from
the top to the bottom of the serpin (c. 70Å), and the resulting pulling force exerted on the
catalytic loop results in a conformational distortion of the protease [53]. The acyl-enzyme
intermediate is thus trapped, with deacylation prevented, largely because of the destruction of
the oxyanion hole. Two structures of final complexes have been solved by X-ray
crystallography [54,55], with one showing an additional distortion of c. 37% of the protease
structure [55]. This mechanism is particularly well suited to tightly regulated processes such
as hemostasis and fibrinolysis because inhibition is irreversible, and the conformational
changes in the serpin and the protease alter cofactor interactions. An example of the physiologic
relevance of the conformational change in the protease component of the complex is the
complete destruction of thrombin’s exosite I in complex with serpins [56]. Thus, when PCI
inhibits thrombin bound to thrombomodulin the interaction with thrombomodulin is broken,
allowing the serpin-protease complex to diffuse away so that another thrombin molecule can
bind [57].
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Because serpin specificity is determined largely by the rate of formation of the Michaelis
complex, cofactors that bind to serpins (and sometimes the protease) can radically alter
specificity [51]. Table 1 presents serpin second order rates of protease inhibition in the presence
and absence of relevant cofactors. The best understood cofactor for serpins is the
glycosaminoglycan (GAG), heparin. It binds to and activates most of the serpins involved in
hemostasis and thrombosis [58]. Acceleration of protease inhibition is generally conferred
through a template effect where the protease and the serpin bind to the same heparin chain.
The hypothesis is that this co-occupation will limit the diffusional freedom from three to one
dimension to increase the likelihood (rate) of encounter. In addition, heparin also provides a
bridge between the serpin and the protease to help stabilize the Michaelis complex. However,
heparin and other GAGs are also capable in some cases of altering the conformation of the
serpin to permit more rapid complexation with proteases. The best-characterized examples are
AT and HCII, whose activation by heparin is the basis of its therapeutic anticoagulant effect.
In the next sections we describe each of the serpins involved in hemostasis and fibrinolysis,
their targets, the role of cofactors and available structural data.
Serpins in hemostasis and fibrinolysis
Antithrombin: SERPINC1
Antithrombin is a 58 kDa, 432 amino acid glycoprotein [59], synthesized in the liver,
circulating at approximately 150 μg mL-1 with a half-life of c. 3 days [60]. It is the most
important physiological inhibitor of the coagulation pathway [61]. As its name implies, AT
inhibits thrombin. In addition, AT is capable of inhibiting all of the other proteolytic
coagulation factors (e.g. FIXa, Xa and XIa). The predominance of its anticoagulant activity,
however, is focused on the regulation of FXa, FIXa and thrombin. Measurement of thrombin-
AT (TAT) complex is used as a marker of hemostatic activation and helps diagnose thrombotic
events [62]. Thrombin bound to fibrin, clot-bound thrombin, is protected from inhibition by
AT [63]. This may explain the occurrence of rethrombosis after fibrinolytic therapy as clot-
bound thrombin is released from the dissolving hemostatic plug [64].
The anticoagulant activity of AT is dependent on its cofactor, heparin. Consisting of variably
sulfated repeating disaccharide units, heparin can have a molecular weight ranging from 3 to
40 kDa [65-67]. A unique pentasaccharide sequence in heparin is responsible for the high
affinity binding to AT [68]. In vivo, forms of heparin relevant to AT include heparan sulfate,
found on the endothelium, and heparin released from endothelium-associated mast cell
granules. The interaction of AT with heparan sulfate on the endothelium and subendothelium
localizes AT activity to the vessel wall and maintains its normal, non-thrombogenic nature
[60]. AT is expressed as both an α-form and a β-form. α-AT represents 90% of AT and is
glycosylated at all four positions. While comprising only 10% of AT, β-AT, which is not
glycosylated at one position (N135), has a higher affinity for heparin and is thought to exert
an overall larger anticoagulant effect [69].
Heparin uses two distinct mechanisms to accelerate protease inhibition by AT. AT undergoes
a well-characterized conformational change upon heparin binding, which expels the N-
terminus of the RSL from β-sheet A (Fig. 3). This ‘liberation’ of the RSL is sufficient to confer
the majority of the acceleration of FIXa and FXa inhibition, but thrombin inhibition is not
appreciably affected. Recently, the structures of the AT-heparin-protease Michaelis complexes
have been solved [54,70] revealing the interactions behind the allosteric and template
mechanisms (Fig. 3B).
In addition to its anticoagulant activity, AT has been shown to have anti-inflammatory and
anti-angiogenic functions. These properties are independent of AT’s inhibitory activity. AT
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regulates inflammation by signaling through heparan sulfate on endothelial and leukocyte cell
surfaces [71]. Latent and cleaved AT exert anti-angiogenic effects [72] by binding cell surface
heparan sulfate. This blocks fibroblast growth factor-2 and vascular endothelial cell growth
factor from forming pro-angiogenic ternary signaling complexes with their protein receptors
and the heparin sulfate co-receptors [73].
Antithrombin in disease
Inherited and acquired AT deficiency predisposes individuals to different degrees of
thrombotic disease. The severity of thromophilia can be exacerbated by other risk factors for
thrombosis. Inherited AT is classified as type I or type II. Type I deficiencies, which generally
confer a higher thrombotic risk, are caused by genetic mutations that impair the synthesis and
secretion of AT. Type II deficiencies are caused by genetic mutations that functionally impair
AT. Variations in the degree of thrombophilia in inherited AT deficiencies can be attributed
to homozygosity vs. heterozygosity and where the mutation lies in the AT structure [74]. An
up-to-date database of AT mutations can be found online at
http://www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin [75].
Some research suggests that certain mutations predispose AT to convert to its latent form,
which preferentially dimerizes with native β-AT. Dimerization reduces the presence of highly
active AT monomers, thus increasing thrombogenicity [76]. Concern has been raised that
therapeutic preparations of AT-concentrates (contain > 10% latent AT) might have thrombotic
effects. However, a recent study demonstrated that the addition of latent AT alone does not
decrease the activity of AT in plasma [77]. Other mutated forms of AT do not show impaired
activity or decreased AT levels in the standard hospital laboratory assays despite associated
thrombophilia. In particular, the AT Cambridge II (A384S) variant was undetected by some
protocols, but estimated to be the most frequent cause of AT deficiency in Caucasian
populations [78]. These results suggest a need for alternative methods for detection of AT
deficiencies [79].
Antithrombin-related treatments for coagulation disorders
Therapeutic unfractionated heparin (UFH), derived from porcine mucosa, is one of the most
commonly used anticoagulant agents administered for treatment and prophylaxis of thrombotic
events. Additionally, UFH is used to coat blood collection tubes and surgical devices to prevent
clotting on their surfaces. UFH’s primary mechanism of action is to accelerate AT’s inhibition
of thrombin, FXa and FIXa. UFH also accelerates thrombin inhibition by other circulating
serpins. It has a very short half-life and optimal dosing of heparin is notoriously difficult to
achieve, therefore requiring frequent monitoring [80]. Still in trials, an orally available form
of heparin, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate bound heparin or SNAC-
heparin, has dose-dependent anti-thrombotic effects, and has an efficacy comparable with low-
molecular weight heparin in reducing venous thrombosis in patients undergoing hip
replacement surgery [81]. Contra-intuitively, heparin can cause a dangerous thrombotic
condition called heparin-induced thrombocytopenia (HIT). In this autoimmune reaction
antibodies develop against platelets [82]. Currently in development stages, synthetic
oligosaccharide heparin mimetics show thrombin and FXa inhibition comparable with UFH
without inducing HIT and with far fewer side effects [83].
Low-molecular-weight heparin (LMWH) is a fractionated preparation of heparin fragments
between 1 and 10 kDa with an enriched population of high affinity pentasaccharide sequences.
Because of the smaller average size, LMWH acts predominantly by inducing conformational
changes in AT, the mechanism which activates FXa. It has a longer half-life than UFH and
does not need coagulation monitoring. LMWH also has significantly reduced risk of HIT.
Multiple LMWH variants are available or in clinical trials [84].
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Fondiparinux and idraparinux are synthetic pentasaccharide sequences derived from heparin,
which activate AT to inhibit FXa specifically. Because of this the single target, the side effect
of over-anticoagulation, bleeding, is reduced. Both have longer half-lives than LMWH.
Additionally, neither preparation causes HIT [84,85].
Thrombotic events because of AT deficiency are treated with AT purified from human plasma.
A covalent AT-heparin complex is currently under preliminary investigations for possible use
as a novel anticoagulant because unlike AT or heparin alone, it is able to inhibit clot-bound
thrombin [86].
Heparin cofactor II: SERPIND1
HCII is a 66.5 kDa, 480 amino acid glycoprotein synthesized in the liver circulating at c. 80
μg mL-1 with a half-life of 2-3 days. HCII inhibits thrombin in the presence of many polyanionic
molecules including the GAGs heparin and dermatan sulfate [12]. A unique hexasaccharide
sequence within dermatan sulfate has been determined to be responsible for its high affinity
binding to HCII [87]. Dermatan sulfate does not accelerate any other serpin activity. HCII has
a unique N-terminal extension of c. 80 residues that contains two acidic regions, critical for its
GAG-associated anti-thrombin activity [88]. HCII inhibits thrombin and clot-bound thrombin,
but not other coagulation proteases [12]. Evidence suggests that HCII contributes 20-30% to
thrombin inhibition in coagulation. Neither humans nor mice deficient in HCII exhibit
thrombophilia under normal conditions [89]. However, HCII homozygous deficient mice form
occlusive thrombi faster than wild-type mice after photochemical vascular endothelial cell
injury to the carotid artery [90]. Recent data suggest that the primary physiological function
of HCII is to inhibit thrombin’s non-hemostatic roles such as in the development of
atherosclerosis. Elevated levels of HCII are shown to protect against atherosclerosis and
restenosis [91-93].
The structure of native HCII was solved in 2002 and revealed a surprising resemblance to
native AT [88], with the N-terminus of the RSL inserted into β-sheet A (Fig. 3). As HCII also
shares a similar heparin binding site along helix D [9,94], it was proposed that HCII underwent
a similar conformational change upon heparin binding [88]. Recently, it was shown that the
smallest heparin length capable of tight binding to HCII was 14 monosaccharide unit chains,
and that the majority of the acceleration effect was due to this allosteric change in HCII
conformation [95]. Disappointingly, however, the native structure could not resolve the
position of the N-terminal extension. Several mutagenesis studies concluded that the acidic tail
binds to the basic heparin binding site in native HCII [94], but it is still unclear how the tail
interacts with the body of HCII in the native state. From the structure of HCII bound to S195A
thrombin [88] it was clear how the tail confers specificity to thrombin. The tail binds to exosite
I of thrombin in a manner similar to hirudin, primarily through hydrophobic contacts. The tail
was found sandwiched between thrombin and the body of HCII, essentially providing a shared
exosite (Fig. 3B). A complex allosteric mechanism has been proposed based on these structures,
supporting biochemical studies and analogy to AT [52,58].
HCII-related treatments for coagulation disorders
As alternatives to heparin-based treatments, dermatan sulfate derivatives and other polyanionic
molecules that act to accelerate HCII’s antithrombotic activity are being investigated. They
are of particular interest for use in HIT, AT deficiency and for the inhibition of clot-bound
thrombin. Two types of fractionated dermatan sulfate enriched for the hexasaccharide sequence
(Intimatan™ and Desmin™) have been tested in humans [96,97]. Intimatan is beginning Phase
I trials. Other HCII agonists in laboratory investigations include over-sulfated dermatan sulfate
[98], fucosylated chondroitin sulfate [99] and fucoidan [100].
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Protein Z-dependent protease inhibitor: SERPINA10
ZPI is a 72 kDa, 444 amino acid glycoprotein, synthesized in the liver, circulating at c. 1.5
μg mL-1. In the presence of protein Z, phospholipids and calcium, ZPI rapidly inhibits FXa.
In the absence of cofactors, ZPI also inhibits FXIa and can be accelerated 2-fold by heparin.
It is thought that the major physiological function of ZPI is to attenuate the coagulation response
prior to the formation of the prothrombinase complex [101]. In humans, mutations in ZPI are
associated with increased risk of venous thrombosis[102-104]. Additionally, reductions in
protein Z plasma concentrations result in an aggravated thromboembolic risk in humans and
mice with factor V Leiden (FV Leiden) [105].
Protein C inhibitor: SERPINA5
PCI is a 57 kDa, 387 amino acid glycoprotein [106], synthesized in the liver, circulating at c.
5 μg mL-1. It is also found in other bodily fluids, including urine, saliva, amniotic fluid, milk,
tears and seminal fluid [107]. PCI is a heparin-binding serpin that inhibits many proteases,
including APC [108], IIa, IIa bound to TM [57], tPA and uPA [109]. PCI may have contrary
anticoagulant and procoagulant functions depending on the target protease and the presence
of specific cofactors. In the presence of heparin, PCI is anticoagulant, inhibiting the proteolytic
cleavage of fibrinogen by thrombin. However, in the presence of TM, PCI is procoagulant,
inhibiting the activation of PC by thrombin [9].
The structures of RSL-cleaved PCI [106] and of native PCI (PDB #2HI9 and #2OL2) (Fig.
3A) have now been solved, revealing a typical serpin structure with some notable differences.
The RSL of PCI is unusually long and flexible, accounting for its broad protease specificity,
and its heparin-binding site is found along the highly basic helix H. The effect of heparin on
PCI activity can either be to accelerate protease inhibition (e.g. APC) [110] or to abrogate it
(tissue kallikrein) [111]. The position of the heparin binding site close to the protease docking
site may help explain this property.
Protein C inhibitor in disease
PCI is not synthesized by the liver in mice, and thus PCI is unlikely to play a role in hemostasis
or fibrinolysis in the mouse [112]. Transgenic mice that over-express human PCI (hPCI)
provide evidence of PCI’s ability to inhibit thrombin, APC and tPA. These mice do not exhibit
symptoms of pulmonary hypertension induced by monocrotaline. TAT complexes are reduced
compared with their wild-type counterparts, suggesting that PCI competes with AT to inhibit
thrombin. Additionally, a decrease in free tPA and subsequent reduction in fibrinolysis is seen.
Finally, when APC was administered for endotoxemia, hPCI-expressing transgenic mice
demonstrated a reduction in the anticoagulant and anti-inflammatory effects of the treatment
[113]. Male homozygous PCI-knockout mice were infertile because of abnormal
spermatogenesis caused by loss of the Sertoli cell barrier [114] because of unregulated
proteolytic activity.
In humans, APC-PCI complex is indicative of atherosclerosis and aortic aneurysms [115], an
early indicator of myocardial infarction [116] and predicts poor patient outcome after aortic
surgery [117]. Additionally, APC-PCI complex is increased (4-fold) in patients with FV Leiden
who have suffered a previous venous thrombosis [118]. PCI alone has been shown to be
elevated in survivors of acute coronary events [119].
α1-Protease inhibitor: SERPINA1
α1PI, historically known as α1-antitrypsin, is a 51 kDa, 394 amino acid glycoprotein,
synthesized in the liver, circulating at c. 1.3 mg mL-1 with a half-life of 4.5 days (structure
shown in Fig. 2). Its physiological target is neutrophil elastase [120]; however, it has also been
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shown to inhibit APC in a heparin-independent manner [31]. In pediatric ischemic stroke
patients, α1PI levels were significantly increased independent of other prothrombotic factors.
Some authors suggest this pathology is due to APC inhibition [121].
α1PI is not thought to contribute significantly to coagulation. However, a variant of the protein
(α1PIPittsburgh) with a reactive site mutation (M358R) can cause a fatal bleeding disorder
[122]. The Met to Arg polymorphism creates a potent inhibitor of several coagulation serine
proteases, especially thrombin and APC, that is not dependent on heparin or other cofactors
[123]. Therapies utilizing recombinant α1PIPittsburgh were considered but abandoned because
of side-effects of promiscuous protease inhibition [124,125].
α2-Antiplasmin: SERPINF2
α2AP is a 63 kDa, 452 amino acid glycoprotein, synthesized in the liver, circulating at c. 70
μg mL-1 with a half-life of 2.6 days [42,126,127]. α2AP is the primary physiological inhibitor
of plasmin, but has also been reported to inhibit other enzymes such as trypsin, elastase and
APC. Homozygous deficiency of α2AP results in uncontrolled fibrinolysis and subsequent
severe hemorrhagic tendencies [126,128]. While α2AP has all of the key structural features of
the serpin family, it uniquely has both N- and C-terminal extensions of 42 and 55 residues,
respectively [42,129]. In thrombus formation, the N-terminal region of α2AP is cross-linked
to fibrin by FXIIIa, and the C-terminal Lys binds to the Lys-binding site of plasmin. The rate
of fibrinolysis is proportional to cross-linked α2AP.
Plasminogen activator-1: SERPINE1
PAI-1 is a 50 kDa, 379 amino acid glycoprotein, synthesized in endothelial cells, platelets and
other mesenchymal cells surrounding the vasculature [130-132]. This serpin is relatively
unstable, with a half-life of 1-2 h in circulation [133]. However, PAI-1 is found bound to the
extracellular matrix protein, vitronectin (VN) [134,135]. The PAI-1-VN complex has an
enhanced half-life of 4-6 h [133]. PAI-1 regulates both tPA and uPA and is considered the
main physiological inhibitor of plasminogen activation [32,33,43,136]. As platelets are
activated following vessel injury, they release PAI-1 to protect the developing thrombus from
premature fibrinolysis. Later in the coagulation process, tPA and plasminogen/plasmin are
bound to fibrin within the thrombus, which protects tPA from inhibition by PAI-1, resulting
in plasmin generation and fibrinolysis [32,33,43,136].
Several structures of PAI-1 have been solved, but, because of its rapid conversion to the latent
form, all structures of native PAI-1 are of a stabilized quadruple mutant [137-139]. Although
the structure shows a native state similar to α1PI, not AT and HCII, some mutagenesis studies
suggest an equilibrium for wild-type PAI-1 where the native state is in equilibrium between
α1PI-like and AT-like states [140]. The structure of the stabilized mutant bound to the
somatomedin domain of VN revealed the mechanism of stabilization of the native state through
a blocking of the expansion of β-sheet A [135] (Fig. 3B).
PAI-1 can also inhibit APC [30] and thrombin [15,141] in the presence of VN and/or heparin.
It is not known to what extent these activities contribute to coagulation. Previously, it has been
shown that APC cleaves PAI-1, inactivating the serpin [142,143]. Recently, it has been shown
that PAI-1 inhibits APC and the rate of inhibition increases in the presence of VN c. three
hundredfold [30].
Plasminogen activator-1 in disease
Studies show that PAI-1 levels are sensitive to many different pathophysiological factors and
increased synthesis of PAI-1 contributes to numerous cardiovascular disease states. In
metabolic syndrome, both glucose and insulin increase PAI-1 synthesis in vascular endothelial
RAU et al. Page 9













and smooth muscle cells [144]. Controlling hyperglycemia in type 2 diabetes results in a
decrease in PAI-1 levels. One of the clinical benefits of ‘statins’ may be due to their decrease
of PAI-1 expression and simultaneous increase of tPA expression, altering the balance of the
fibrinolytic pathway [145,146]. Circadian clock proteins, including CLOCK, BMAL and CRY,
regulate PAI-1 gene expression, which may explain the increased risk of adverse
cardiovascular events in the morning [147]. Inhibition of nitric oxide synthase induces PAI-1
expression, which contributes to the development of perivascular fibrosis [148]. Increased
PAI-1 levels are associated with coronary artery disease and myocardial infarction. However,
studies examining the association of cardiovascular disease with a polymorphism within the
PAI-1 promoter region (4 G/5 G) which increases the expression of PAI-1 are controversial
[149]. Stents with rapamycin and paclitaxel are used in interventional cardiology because of
the antiproliferative effects of these drugs [150,151]. These stents have been shown to be
associated with an increased risk of thrombosis and it is speculated that this may be due to an
up-regulation of PAI-1 by rapamycin and paclitaxel [152]. There is also strong evidence for a
role of PAI-1 in cancer metastasis independent of its protease inhibitory activity [41,153,
154].
Effectors of plasminogen activator inhibitor-1 activity and synthesis
Physiological levels of PAI-1 provide crucial regulation of fibrinolysis, yet excess levels
contribute to disease. Numerous factors have been found that up-regulate PAI-1 expression
and secretion, including inflammatory cytokines, angiotensin II, aldosterone, transforming
growth factor-β, and very low density lipoproteins [43,155,156]. Monoclonal antibodies have
been prepared against PAI-1, which express inhibitory activity by: (i) preventing the formation
of the encounter complex between PAI-1 and tPA/uPA, (ii) increasing PAI’s susceptibility to
cleavage by target proteases, and (iii) promoting the tendency of PAI-1 to become latent and
inactive [157]. Sequence-specific catalytic DNA enzyme, short-interfering RNA structures and
antisense technology have all been used to down-regulate PAI-1 levels [158]. Negatively
charged organochemical compounds have been found to bind to a hydrophobic site on PAI-1
and induce polymerization and inactivation. Finally, several small molecules (XR5118,
ZK4044 and PAI-039) have been developed to inhibit PAI-1 activity by either reduction of
accessibility to the RSL, by promoting a latent-like state or by favoring a substrate-like
conformation [159-167].
Closing statement
In this State of the Art manuscript, we have described our current knowledge of serpins that
regulate hemostasis and fibrinolysis. Utilizing the ‘suicide substrate’ mechanism unique to
serpins AT, HCII, ZPI, α1PI, PCI, α2AP and PAI-1 provides rapid and specific inhibition of
the activated serine proteases in the coagulation, protein C and fibrinolytic pathways. These
pathways are not single independent systems, but they represent a dynamic balance between
procoagulant, anticoagulant, profibrinolytic and antifibrinolytic states with serpins playing
multiple and sometimes conflicting roles. While we have learned a considerable amount about
their physiological control, their structure, related activities and regulation by local cofactors,
much is left to be understood. Of note, this includes deciphering the primary physiologic roles
of HCII and PCI, resolving the crystal structures of ZPI and α2AP, and learning more about
the non-hemostatic functions of AT and PAI-1. Continued research with the less-studied
serpins such as ZPI and α2AP will undoubtedly provide useful information about control of
hemostasis and fibrinolysis and of serpins in general. The serpins described in this paper have
a multitude of functions, which under some circumstances contribute to disease, but which
often can be manipulated for the benefit of medicine. Therefore, it is of paramount importance
that we continue the investigations of serpins in thrombosis, hemostasis and fibrinolysis.
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Serpin regulation of coagulation, protein C and fibrinolytic pathways. Serpins and inhibitory
functions are shown in red, thrombin activity is shown in cyan. Prothrombinase and tenase
complexes are shown in gray boxes. Coagulation is initiated by the exposure of tissue factor
to factor VIIa shown in a gray oval. The symbol * indicates degradation. Necessary cofactors,
Ca++, phospholipids, proteins S and Z, vitronectin and GAGs are not shown to maintain the
simplicity of the schematic.
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Serpin structure and mechanism of protease inhibition. (A) The shared serpin fold is illustrated
by the structure of the prototypical native serpin α1PI. The ‘classic’ orientation shown on the
left places the RSL (yellow) on top and the main β-sheet A (red) to the front. Sheets B and C
are blue and orange, respectively, and helices A, D and H are colored green, cyan and magenta.
The accessibility of the RSL is illustrated by rotating the molecule by 110° to the left along
the long axis. It shows how the P1-P1′ (rods) scissile bond is exposed for proteolytic attack.
Also clearer in this orientation are helices D and H, which are the heparin binding helices. (B)
The serpin mechanism of protease inhibition is minimally expressed as a two-step process. In
the first step, native serpin (ribbon with the P1 and P1′ residues as magenta balls) interacts
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reversibly with a protease (surface representation, colored according to temperature factors
from blue to red) to form the Michaelis complex (middle). After formation of the acyl-enzyme
intermediate the protease is flung to the opposite pole of the serpin and its catalytic architecture
is destroyed, and consequently there is a loss of ordered structure (notice the smaller size and
increase in temperature factors).
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Native and complexed serpin structures. (A) The native structures of important hemostatic and
fibrinolytic serpins are shown as ribbon diagrams, colored essentially as in Fig. 2. The
monomeric structure of antithrombin is shown in the left panel, and is similar to that of heparin
cofactor II (HCII) with the partial insertion of the N-terminal portion of the reactive site loop
(RSL). A modeled position for the N-terminal tail of HCII is shown in magenta although its
true position is not known. For AT, HCII and plasminogen activator inhibitor-1 the heparin
binding helix (helix D) is shown in cyan, but for protein C inhibitor (PCI) heparin binds to
helix H (blue). The increased size and flexibility of the RSL of PCI is also evident from this
depiction. (B) Some important serpin complexes are shown. Using S195A proteases it was
possible to obtain the structures of the AT Michaelis complexes with thrombin (magenta) and
FXa (magenta) with their activating synthetic heparins (SR123781 and fondaparinux, rods).
Similarly, the HCII-thrombin (blue) complex was also solved. The somatomedin (SMB)
domain of VN (magenta) binds to s1A and helix E to prevent the latent transition through
expansion of sheet A.
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